FDA授予tarlatamab-dlle加速批准用于广泛期小细胞肺癌
正文 · 中文译文
FDA授予tarlatamab-dlle加速批准用于广泛期小细胞肺癌 癌症批准 肿瘤(癌症)/血液系统恶性肿瘤批准通知 进行中 | 癌症加速批准 已验证临床获益 | 癌症加速批准 已撤回 | 癌症加速批准 其他 | 癌症加速批准 2024年5月16日,美国食品药品监督管理局(FDA)授予tarlatamab-dlle(Imdelltra,安进公司)加速批准,用于在铂类化疗期间或之后出现疾病进展的广泛期小细胞肺癌(ES-SCLC)。 Imdelltra的完整处方信息将在此处发布。 疗效与安全性 疗效在DeLLphi-301 [NCT05060016]研究中评估,该研究为一项开放标签、多中心、多队列研究,纳入99例经铂类化疗后疾病进展的复发/难治性ES-SCLC患者。排除有症状脑转移、间质性肺病或非感染性肺炎以及活动性免疫缺陷的患者。患者接受tarlatamab治疗直至疾病进展或出现不可接受的毒性。 主要疗效结局指标为根据RECIST 1.1由盲法独立中心审查评估的客观缓解率(ORR)和缓解持续时间(DOR)。ORR为40%(95% CI:31,51),中位DOR为9.7个月(范围2.7,20.7+)。在69例有铂敏感性状态可用数据的患者中,27例铂耐药SCLC(定义为末次铂治疗后<90天进展)患者的ORR为52%(95% CI 32,71),42例铂敏感SCLC(定义为末次铂治疗后≥90天进展)患者的ORR为31%(95% CI 18,47)。 tarlatamab-dlle的处方信息包括针对严重或危及生命的细胞因子释放综合征(CRS)和神经毒性(包括免疫效应细胞相关神经毒性综合征(ICANS))的黑框警告。最常见的不良反应(>20%)为细胞因子释放综合征(CRS)、疲乏、发热、味觉障碍、食欲减退、肌肉骨骼疼痛以及便秘、贫血和恶心。最常见的3级或4级实验室异常(≥5%)为淋巴细胞减少、钠降低、尿酸升高、中性粒细胞总数降低、血红蛋白降低、活化部分凝血活酶时间延长和钾降低。 tarlatamab的推荐剂量为初始剂量1 mg,于第1周期第1天经1小时静脉输注给药,随后于第1周期第8天和第15天给予10 mg,此后每2周给药一次,直至疾病进展或出现不可接受的毒性。 加速审批程序 本综述是在FDA肿瘤卓越中心发起的Project Orbis项目下开展的。Project Orbis为国际合作伙伴之间肿瘤药物的同步提交和审评提供了框架。本次审评中,FDA与巴西卫生监管局(ANVISA)、加拿大卫生部(HC)、以色列卫生部(IMoH)以及英国药品和保健产品监管局(MHRA)合作。参与Project Orbis的其他监管机构的申请审评仍在进行中。 本综述采用了实时肿瘤学审评(RTOR)试点项目,该项目简化了完整临床应用提交之前的数据提交过程,并采用了评估辅助工具(Assessment Aid),这是申请人自愿提交以促进FDA评估的材料。FDA在FDA目标日期之前1个月批准了该申请。 本申请基于总缓解率和缓解持续时间获得了加速批准。持续批准可能取决于临床获益的验证。 本申请获得了优先审评、突破性疗法认定和孤儿药认定。FDA的加速项目在《行业指南:严重疾病药物和生物制品的加速项目》中有描述。 医疗保健专业人员应将所有怀疑与使用任何药物和器械相关的严重不良事件报告至FDA的MedWatch报告系统,或致电1-800-FDA-1088。 对于研究性肿瘤产品的单患者临床试验新药申请(IND)协助,医疗保健专业人员可致电OCE的Project Facilitate,电话240-402-0004,或发送电子邮件至OncProjectFacilitate@fda.hhs.gov。 在X(原Twitter)上关注肿瘤卓越中心 @FDAOncology。 内容更新日期: 05/16/2024 受监管产品 药物 肿瘤学
正文 · 英文原文
FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer Cancer Approvals Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Full prescribing information for Imdelltra will be posted here. Efficacy and Safety Efficacy was evaluated in 99 patients with relapsed/refractory ES-SCLC with disease progression following platinum-based chemotherapy enrolled in DeLLphi-301 [NCT05060016], an open-label, multicenter, multi-cohort study. Patients with symptomatic brain metastases, interstitial lung disease or non-infectious pneumonitis, and active immunodeficiency were excluded. Patients received tarlatamab until disease progression or unacceptable toxicity. The major efficacy outcome measures were overall response rate (ORR) per RECIST 1.1 and duration of response (DOR), as assessed by blinded independent central review. ORR was 40% (95% CI: 31, 51) and median DOR was 9.7 months (range 2.7, 20.7+). Of the 69 patients with available data regarding platinum sensitivity status, the ORR was 52% (95% CI 32, 71) in 27 patients with platinum-resistant SCLC (defined as progression < 90 days after last dose of platinum therapy) and 31% (95% CI 18, 47) in 42 patients with platinum-sensitive SCLC (defined as progression ≥ 90 days after last dose of platinum therapy). The prescribing information for tarlatamab-dlle includes a Boxed Warning for serious or life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS). The most common adverse reactions (>20%) were cytokine release syndrome (CRS), fatigue, pyrexia, dysgeusia, decreased appetite, musculoskeletal pain, and constipation, anemia and nausea. The most common Grade 3 or 4 laboratory abnormalities (≥5%) were decreased lymphocytes, decreased sodium, increased uric acid, decreased total neutrophils, decreased hemoglobin, increased activated partial thromboplastin time, and decreased potassium. The recommended tarlatamab dose is an initial dose of 1 mg administered as an intravenous infusion over 1 hour on Cycle 1 Day 1, followed by 10 mg on Cycle 1 Day 8 and Day 15 then every 2 weeks thereafter until disease progression or unacceptable toxicity. Expedited Programs This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Brazilian Health Regulatory Agency (ANVISA), Health Canada (HC), Israel’s Ministry of Health (IMoH), and United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The application reviews are ongoing at the other regulatory agencies involved with Project Orbis. This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application 1 month ahead of the FDA goal date. This application was granted accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification of clinical benefit. This application was granted priority review, breakthrough designation, and orphan drug designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. Follow the Oncology Center of Excellence on X (formerly Twitter) @FDAOncology. Content current as of: 05/16/2024 Regulated Product(s) Drugs Oncology